<DOC>
	<DOCNO>NCT00169481</DOCNO>
	<brief_summary>Three dose primary vaccination 11-valent pneumococcal conjugate vaccine administer concomitantly Infanrix™ hexa healthy infant 8 16 week age time first vaccination .</brief_summary>
	<brief_title>A Study Children With Different Formulations GSK Biologicals ' 11 Valent Pneumococcal Conjugate Vaccine</brief_title>
	<detailed_description>Test group : 9 group receive different formulation 11PN-PD-DiT vaccine + DTPa-HBV-IPV/Hib ( Infanrix™ hexa ) Comparator : 11Pn-PD + Infanrix™ hexa Control : Prevenar® + Infanrix™ hexa</detailed_description>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Inclusion criterion : Male female age 816 week time first vaccination , write informed consent obtain parent/guardian subject . Exclusion criterion : Use investigational nonregistered drug vaccine study vaccine within 30 day preceeding first dose study vaccine , plan use study period . Planned administration/ administration license vaccine foreseen study protocol period start 30 day first dose vaccine ( ) end 30 day last dose .</criteria>
	<gender>All</gender>
	<minimum_age>8 Weeks</minimum_age>
	<maximum_age>16 Weeks</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>